Difficulty: Medium
Average Score: 87%
Practice
A 5-year-old child, recently diagnosed with ileocecal Burkitt lymphoma; lab investigations reveal: serum uric acid 12 mg/dl, serum sodium, 145 meq/dl; serum potassium, 4.5 meq/dl; serum phosphate 4.4 meq/dl; serum calcium, 8.9 mg/dl; blood urea, 22 mg/dl; serum creatinine, 0.8 mg/dl. Of the following, the MOST effective treatment is
Correct answer
D
Rationale
In this scenario, the most effective treatment is option D) recombinant urate oxidase. This is because the child has ileocecal Burkitt lymphoma, a malignancy associated with rapid cell turnover leading to tumor lysis syndrome (TLS). The elevated uric acid level of 12 mg/dl indicates TLS, which can lead to renal failure and other complications if not addressed promptly.
Recombinant urate oxidase (rasburicase) is the treatment of choice for TLS as it rapidly breaks down uric acid into a more soluble form, preventing uric acid crystallization and subsequent renal damage. This therapy is crucial in preventing acute kidney injury and other TLS-related complications.
Option A) excessive hydration is not the most effective treatment as it alone may not be sufficient to rapidly reduce the dangerously high uric acid levels seen in TLS. Option B) sodium bicarbonate is used to alkalinize the urine and prevent uric acid crystallization but is not as effective as recombinant urate oxidase in rapidly lowering uric acid levels. Option C) xanthine oxidase inhibitor (such as allopurinol) is used for chronic management of hyperuricemia but is not as effective as recombinant urate oxidase in the acute setting of TLS.
Educationally, understanding the pathophysiology of TLS and the appropriate management is crucial for healthcare providers caring for pediatric oncology patients. Recognizing the urgency of treating elevated uric acid levels in TLS with recombinant urate oxidase can prevent severe complications and improve patient outcomes.
Recombinant urate oxidase (rasburicase) is the treatment of choice for TLS as it rapidly breaks down uric acid into a more soluble form, preventing uric acid crystallization and subsequent renal damage. This therapy is crucial in preventing acute kidney injury and other TLS-related complications.
Option A) excessive hydration is not the most effective treatment as it alone may not be sufficient to rapidly reduce the dangerously high uric acid levels seen in TLS. Option B) sodium bicarbonate is used to alkalinize the urine and prevent uric acid crystallization but is not as effective as recombinant urate oxidase in rapidly lowering uric acid levels. Option C) xanthine oxidase inhibitor (such as allopurinol) is used for chronic management of hyperuricemia but is not as effective as recombinant urate oxidase in the acute setting of TLS.
Educationally, understanding the pathophysiology of TLS and the appropriate management is crucial for healthcare providers caring for pediatric oncology patients. Recognizing the urgency of treating elevated uric acid levels in TLS with recombinant urate oxidase can prevent severe complications and improve patient outcomes.